

Author index

Volume 52 (2001)

- Abid, K., see Quadri, R. **52**, 161
 Alberti, A., see Benvegnù, L. **52**, 199
 Alisa, A., see Williams, R. **52**, 217
 Andersen, I., see Horváth, A. **52**, 43
 Andersen, O., see Horváth, A. **52**, 43
 Antonio Quiroga, J., see Carreño, V. **52**, 147
- Bailey, K.W., see Smee, D.F. **52**, 251
 Bailey, K.W., see Smee, D.F. **52**, 55
 Bartenschlager, R., V. Lohmann, Novel cell culture systems for the hepatitis C virus **52**, 1
 Baum, E.Z., see Smee, D.F. **52**, 251
 Beljaars, L., see van der Strate, B.W.A. **52**, 225
 Benvegnù, L., A. Alberti, Patterns of hepatocellular carcinoma development in hepatitis B virus and hepatitis C virus related cirrhosis **52**, 199
 Booth, R.J., see Meyer, A.L. **52**, 289
 Branch, A.D., J.L. Walewski, The coming impact of gene expression profiling on the diagnosis and treatment of HCV-associated liver disease **52**, 173
 Bruening, E.E., see Meyer, A.L. **52**, 289
 Burda, M.R., S. Günther, M. Dandri, H. Will, J. Petersen, Structural and functional heterogeneity of naturally occurring hepatitis B virus variants **52**, 125
- Carreño, V., M.A. Rico, M. Pardo, J. Antonio Quiroga, Extended follow-up of anti-HBe-positive patients with chronic hepatitis B retreated with ribavirin and interferon- α **52**, 147
 Carreño, V., see Zeuzem, S. **52**, 181
 Cerino, A., see Mondelli, M.U. **52**, 153
 Chang, W.-Y., see Yu, M.-L. **52**, 241
 Chemin, I., D. Jeantet, A. Kay, C. Trépo, Role of silent hepatitis B virus in chronic hepatitis B surface antigen(–) liver disease **52**, 117
 Chen, M., M. Sällberg, S.N. Thung, J. Hughes, J. Jones, D.R. Milich, Modeling the T-helper cell response in acute and chronic hepatitis B virus infection using T-cell receptor transgenic mice **52**, 99
 Chen, S.-C., see Yu, M.-L. **52**, 241
 Cheung, D., see Gong, Y. **52**, 25
 Chuang, W.-L., see Yu, M.-L. **52**, 241
 Cividini, A., see Mondelli, M.U. **52**, 153
 Colombo, M., Treatment of hepatocellular carcinoma **52**, 209
- Dai, C.-Y., see Yu, M.-L. **52**, 241
 Dandri, M., see Burda, M.R. **52**, 125
 de Man, R.A., see van Nunen, A.B. **52**, 139
 Dunkle, W.E., see Meyer, A.L. **52**, 289
- Erdei, A., see Horváth, A. **52**, 43
- García-Samaniego, J., see Rodríguez-Rosado, R. **52**, 189
 Gizurarson, S., see Horváth, A. **52**, 43
 Gong, Y., A. Wen, D. Cheung, M. Wong, S.L. Sacks, Preclinical evaluation of docusate as protective agent from herpes simplex viruses **52**, 25
 Gordon, Y.J., see Romanowski, E.G. **52**, 275
 Günther, S., see Burda, M.R. **52**, 125
- Harmsen, M.C., see van der Strate, B.W.A. **52**, 225
 Heaton, N., see Williams, R. **52**, 217
 Holm Nielsen, E., see Horváth, A. **52**, 43
 Horváth, A., I. Andersen, K. Junker, B. Lyck Fogh-Schultz, E. Holm Nielsen, S. Gizurarson, O. Andersen, J. Kármán, E. Rajnavölgyi, A. Erdei, S.-E. Svehag, Serum amyloid P component inhibits influenza A virus infections: in vitro and in vivo studies **52**, 43
 Ho, W.-Z., see Ruff, M.R. **52**, 63
 Hsieh, M.-Y., see Yu, M.-L. **52**, 241
 Hughes, J., see Chen, M. **52**, 99
- Janssen, H.L.A., see van Nunen, A.B. **52**, 139
 Jeantet, D., see Chemin, I. **52**, 117
 Jones, J., see Chen, M. **52**, 99
 Junker, K., see Horváth, A. **52**, 43
- Kaneko, H., K. Kato, S. Mori, S. Shigeta, Antiviral activity of NMSO3 against adenovirus in vitro **52**, 281
 Karani, J., see Williams, R. **52**, 217
 Kármán, J., see Horváth, A. **52**, 43
 Käsermann, F., K. Wyss, C. Kempf, Virus inactivation and protein modifications by ethyleneimines **52**, 33
 Kato, K., see Kaneko, H. **52**, 281
 Kay, A., see Chemin, I. **52**, 117
 Kempf, C., see Käsermann, F. **52**, 33

- LaBarre, D.D., see Lowy, R.J. **52**, 261
- Lin, Z.-Y., see Yu, M.-L. **52**, 241
- Lohmann, V., see Bartenschlager, R. **52**, 1
- Lowy, R.J., G.A. Vavrina, D.D. LaBarre, Comparison of gamma and neutron radiation inactivation of influenza A virus **52**, 261
- Lyck Fogh-Schultz, B., see Horváth, A. **52**, 43
- Ly, L., see Smee, D.F. **52**, 251
- Manns, M.P., see Tillmann, H.L. **52**, 83
- Meijer, D.K.F., see van der Strate, B.W.A. **52**, 225
- Melendez-Guerrero, L.M., see Ruff, M.R. **52**, 63
- Meola, A., see Mondelli, M.U. **52**, 153
- Meyer, A.L., E.E. Bruening, W.E. Dunkle, R.J. Booth, B.A. Steinbaugh, J.V.N. Vara Prasad, PD0084430: a non-nucleoside inhibitor of human cytomegalovirus replication in vitro **52**, 289
- Mikovits, J.W., see Ruff, M.R. **52**, 63
- Milich, D.R., see Chen, M. **52**, 99
- Molema, G., see van der Strate, B.W.A. **52**, 225
- Mondelli, M.U., A. Cerino, L. Segagni, A. Meola, A. Cividini, E. Silini, A. Nicosia, Hypervariable region 1 of hepatitis C virus: immunological decoy or biologically relevant domain? **52**, 153
- Mori, S., see Kaneko, H. **52**, 281
- Morrison, A.C., see Smee, D.F. **52**, 251
- Morroni, J., see Smith, R.L. **52**, 19
- Negro, F., see Quadri, R. **52**, 161
- Nicosia, A., see Mondelli, M.U. **52**, 153
- Niesters, H.G.M., see van Nunen, A.B. **52**, 139
- Pardo, M., see Carreño, V. **52**, 147
- Pérez-Olmeda, M., see Rodríguez-Rosado, R. **52**, 189
- Pert, C.B., see Ruff, M.R. **52**, 63
- Petersen, J., see Burda, M.R. **52**, 125
- Quadri, R., L. Rubbia-Brandt, K. Abid, F. Negro, Detection of the negative-strand hepatitis C virus RNA in tissues: implications for pathogenesis **52**, 161
- Rajnavölgyi, E., see Horváth, A. **52**, 43
- Rela, M., see Williams, R. **52**, 217
- Rico, M.A., see Carreño, V. **52**, 147
- Rodríguez-Rosado, R., M. Pérez-Olmeda, J. García-Samaniego, V. Soriano, Management of hepatitis C in HIV-infected persons **52**, 189
- Romanowski, E.G., K.A. Yates, Y.J. Gordon, Antiviral prophylaxis with twice daily topical cidofovir protects against challenge in the adenovirus type 5/New Zealand rabbit ocular model **52**, 275
- Rubbia-Brandt, L., see Quadri, R. **52**, 161
- Ruff, M.R., L.M. Melendez-Guerrero, Q.-e. Yang, W.-Z. Ho, J.W. Mikovits, C.B. Pert, F.A. Ruscetti, Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5) **52**, 63
- Ruscetti, F.A., see Ruff, M.R. **52**, 63
- Sacks, S.L., see Gong, Y. **52**, 25
- Sällberg, M., see Chen, M. **52**, 99
- Schalm, S.W., see van Nunen, A.B. **52**, 139
- Segagni, L., see Mondelli, M.U. **52**, 153
- Shigeta, S., see Kaneko, H. **52**, 281
- Sidwell, R.W., see Smee, D.F. **52**, 251
- Sidwell, R.W., see Smee, D.F. **52**, 55
- Silini, E., see Mondelli, M.U. **52**, 153
- Smee, D.F., K.W. Bailey, M.-H. Wong, R.W. Sidwell, Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice **52**, 55
- Smee, D.F., R.W. Sidwell, A.C. Morrison, K.W. Bailey, E.Z. Baum, L. Ly, P.C. Wagaman, Characterization of an influenza A (H3N2) virus resistant to the cyclopentane neuraminidase inhibitor RWJ-270201 **52**, 251
- Smith, R.L., J. Morroni, C.L. Wilcox, Lack of effect of treatment with penciclovir or acyclovir on the establishment of latent HSV-1 in primary sensory neurons in culture **52**, 19
- Soriano, V., see Rodríguez-Rosado, R. **52**, 189
- Steinbaugh, B.A., see Meyer, A.L. **52**, 289
- Svehag, S.-E., see Horváth, A. **52**, 43
- Thung, S.N., see Chen, M. **52**, 99
- Thursz, M., Genetic susceptibility in chronic viral hepatitis **52**, 113
- Tillmann, H.L., M.P. Manns, GB virus-C infection in patients infected with the human immunodeficiency virus **52**, 83
- Trépo, C., see Chemin, I. **52**, 117
- Tsai, J.-F., see Yu, M.-L. **52**, 241
- van der Strate, B.W.A., L. Beljaars, G. Molema, M.C. Harmsen, D.K.F. Meijer, Antiviral activities of lactoferrin **52**, 225
- van Nunen, A.B., H.L.A. Janssen, L.M.M. Wolters, H.G.M. Niesters, R.A. de Man, S.W. Schalm, Is combination therapy with lamivudine and interferon-alpha superior to monotherapy with either drug? **52**, 139
- Vara Prasad, J.V.N., see Meyer, A.L. **52**, 289
- Vavrina, G.A., see Lowy, R.J. **52**, 261
- Wagaman, P.C., see Smee, D.F. **52**, 251
- Walewski, J.L., see Branch, A.D. **52**, 173
- Wang, L.-Y., see Yu, M.-L. **52**, 241
- Wen, A., see Gong, Y. **52**, 25
- Wilcox, C.L., see Smith, R.L. **52**, 19
- Will, H., see Burda, M.R. **52**, 125
- Williams, R., A. Alisa, J. Karani, M. Rela, N. Heaton, Living related adult-to-adult liver transplantation: meeting the donor shortage **52**, 217
- Wolters, L.M.M., see van Nunen, A.B. **52**, 139
- Wong, M.-H., see Smee, D.F. **52**, 55
- Wong, M., see Gong, Y. **52**, 25
- Wyss, K., see Käsermann, F. **52**, 33
- Yang, Q.-e., see Ruff, M.R. **52**, 63
- Yates, K.A., see Romanowski, E.G. **52**, 275
- Yu, M.-L., W.-L. Chuang, C.-Y. Dai, S.-C. Chen, Z.-Y. Lin, M.-Y. Hsieh, J.-F. Tsai, L.-Y. Wang, W.-Y. Chang, GB virus C/hepatitis G virus infection in chronic hepatitis C patients with and without interferon- α therapy **52**, 241
- Zeuzem, S., V. Carreño, Interleukin-12 in the treatment of chronic hepatitis B and C **52**, 181